JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company had begun treating patients in its LUCIDA (LUx Corneal Transplant Implant Development and Advancement of Therapy) pivotal clinical trial program of LX201, the company’s cyclosporine A (CsA) eluting silicone matrix implant. The LUCIDA pivotal program, which consists of two controlled studies, is investigating the use of LX201 in patients at elevated immune mediated risk of rejection or graft loss subsequent to cornea transplantation.
